NCT06612151View on ClinicalTrials.gov

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2030

Conditions
Small Cell Lung Cancer
Interventions
DRUG

YL201

Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.

DRUG

topotecan hydrochloride for injection

Topotecan hydrochloride will be administered intravenously per prescribing information.

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY